• Necrosulfonamide: Enabling Precision Necroptosis Research in

  2026-04-30

  This article unpacks the mechanistic rationale and translational significance of Necrosulfonamide (NSA) for dissecting MLKL-driven necroptosis, drawing on recent cardiovascular injury models and providing strategic guidance for researchers leveraging NSA in complex disease contexts.

• SARS-CoV-2 N Protein Disrupts GADD34-Driven Innate Immunity

  2026-04-29

  Liu et al. reveal that the SARS-CoV-2 nucleocapsid protein suppresses the host antiviral response by sequestering GADD34 mRNA into atypical stress foci, inhibiting interferon pathway activation. These insights clarify a novel viral immune evasion mechanism and highlight new targets for RNA virus research.

• Cyclophosphamide: Applied Protocols for Cancer Research Succ

  2026-04-29

  Cyclophosphamide, a benchmark alkylating chemotherapeutic agent, empowers precise apoptosis induction and immune modulation in diverse cancer research and transplantation models. This guide delivers actionable protocols, troubleshooting strategies, and translational insights to maximize reproducibility and experimental impact.

• Thiazovivin: Practical Guidance for ROCK Inhibition in Stem

  2026-04-28

  Thiazovivin is a potent ROCK inhibitor optimized for enhancing fibroblast reprogramming and human embryonic stem cell (hESC) survival in well-defined stem cell workflows. It should be used where robust cell viability and efficient iPSC generation are required, but is not intended for diagnostic or clinical applications beyond research.

• Nanozyme-Driven Clearance of Intramacrophage Bacteria Boosts

  2026-04-28

  This study introduces a self-activatable polymeric nanozyme that eradicates tumor-associated Fusobacterium nucleatum within macrophages, thereby remodeling the immunosuppressive tumor microenvironment in colorectal cancer (CRC). By enhancing the efficacy of CD47 blockade immunotherapy, the research offers mechanistic insights and a translational framework for overcoming immune resistance in CRC.

• Cisplatin in Cancer Research: Workflows, Assays & Troublesho

  2026-04-27

  Cisplatin (CDDP) stands as a cornerstone DNA crosslinking agent for cancer research, enabling robust apoptosis and chemoresistance studies both in vitro and in vivo. Explore enhanced workflows, troubleshooting strategies, and practical insights anchored by the latest mechanistic evidence and APExBIO’s validated supply.

• CHIR-99021 (CT99021): Defining Precision in Pluripotency & O

  2026-04-27

  Explore how CHIR-99021 (CT99021) enables next-gen stem cell assays by precisely modulating pluripotency and differentiation. This article reveals practical insights rooted in organoid model innovation and advanced GSK-3 inhibition.

• ACE Inhibitor-Mediated Angioedema: Pathogenesis and Clinical

  2026-04-26

  This article examines the mechanistic basis, epidemiology, and clinical challenges of angioedema induced by ACE inhibitors, as detailed in the reference study by Montinaro and Cicardi. It highlights the significance of bradykinin accumulation, genetic predisposition, and the nuanced management strategies for affected patients, with attention to translational implications for gastrointestinal researchers.

• Propranolol Modulates Burn-Induced Metabolic Pathways: RCT I

  2026-04-25

  This randomized controlled trial demonstrates that propranolol treatment in severely burned patients significantly normalizes key metabolic and lipidomic pathways in adipose tissue, shifting the profile towards an anti-inflammatory state and improving clinical outcomes. These findings elucidate the mechanistic basis for propranolol’s benefits in burn care and inform future metabolic intervention strategies.

• H-89: Optimizing cAMP-Dependent Protein Kinase Inhibition Wo

  2026-04-24

  H-89 from APExBIO is the gold-standard cAMP-dependent protein kinase inhibitor for dissecting cAMP signaling in metabolic, osteogenic, and cell proliferation studies. This guide bridges the latest mechanistic insights with actionable protocols and troubleshooting strategies, empowering researchers to achieve reproducible, high-specificity results.

• Applied Workflows with Recombinant Human EGF: Precision and

  2026-04-24

  Recombinant human EGF empowers advanced cell migration, proliferation, and mucosal healing studies with unmatched consistency. This article delivers protocol-driven guidance, troubleshooting insights, and workflow enhancements that set APExBIO’s EGF apart in translational research.

• HyperFluor™ 488 Goat Anti-Rabbit IgG (H+L) Antibody: Practic

  2026-04-23

  The HyperFluor™ 488 Goat Anti-Rabbit IgG (H+L) Antibody addresses the need for reliable, high-sensitivity fluorescent detection of rabbit primary antibodies in immunofluorescence, flow cytometry, and microscopy workflows. It is best suited for protocols requiring robust signal amplification and minimal cross-reactivity, but should not be used outside validated immunoassay contexts or with non-rabbit primaries.

• Substance P (B6620): Technical Guidance for CNS and Immunoas

  2026-04-23

  Substance P enables precise modeling of pain transmission, inflammation, and immune response modulation in CNS-focused research. This product is best suited for applications requiring a high-purity tachykinin neuropeptide with well-characterized solubility and receptor targeting properties. It should not be used for diagnostic or therapeutic purposes or in workflows demanding long-term solution stability.

• Recombinant Human Growth Hormone: Advanced Cell Assay Workfl

  2026-04-22

  Unlock the full potential of Recombinant Human Growth Hormone (GH) in cell proliferation and mechanistic signaling studies. This guide delivers actionable protocols, troubleshooting insights, and the latest mechanistic breakthroughs to optimize GH-driven research workflows.

• Structure-Based Screening Reveals NSP15 Inhibitors for SARS-

  2026-04-22

  This study leverages structure-based virtual screening to identify natural product inhibitors targeting NSP15, a key endoribonuclease implicated in immune evasion by SARS-CoV-2. The work highlights thymopentin and oleuropein as potent and stable binders, providing a foundation for future antiviral development.

16869 records 1/1125 page Next 12345 下5页 Last page